Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium.
OBJECTIVE
This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection.


METHODS
Ninety American Society of Anesthesiology (ASA) physical status I or II patients, aged 18-65 years, were randomly divided into two groups that received either a 1.5-ml solution containing 1.5 mg nafamostat mesilate diluted in a 5% glucose solution or a 1.5-ml 5% glucose solution. Anesthesia was induced by 5 mg/kg 2.5% thiopental. After confirming loss of consciousness, a tourniquet was applied to the mid forearm and tightened to block venous flow. The test solution was then administered, 1 min after which the tourniquet was removed and 0.6 mg/kg rocuronium was administered. Each patient's response to rocuronium injection was graded on a four-point scale in a double-blind manner. Activated coagulation time and plasma potassium concentration were measured before and 5 and 10 min after nafamostat administration.


RESULTS
The incidence of withdrawal response was 68.9% in the control group and 24.4% in the nafamostat group (P < 0.001). The number of patients showing generalized movement (response 4) with the rocuronium injection was significantly lower in nafamostat group [1 (2.2%)] than the control group [15 (33.3%)], P < 0.001. Five and 10 min after nafamostat administration, measured potassium and activated coagulation time were similar to baseline values.


CONCLUSIONS
Pretreatment with 1.5 mg nafamostat mesilate decreased withdrawal response associated with rocuronium injection.
Kim
Yoon Hee
YH
Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, 640 Daesa-dong, Jung-gu, Daejeon, 301-721, Korea. yhkim0404@cnu.ac.kr
Go
Young Kwon
YK
Lee
Jung Un
JU
Chung
Woo Suk
WS
Shin
Yong Sup
YS
Han
Kyu Cheol
KC
Shin
Ji Eun
JE
Lee
Suk Hoon
SH
D000328:Adult; D000732:Androstanols / Q000009:adverse effects*; D001550:Benzamidines; D004311:Double-Blind Method; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors*; D008297:Male; D008875:Middle Aged; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects*; D000077123:Rocuronium
D000732:Androstanols; D001550:Benzamidines; D006146:Guanidines; D003473:Neuromuscular Nondepolarizing Agents; D007610:Kallikreins; D000077123:Rocuronium; C032855:nafamostat